DMT
Cava soars in stock market debut — hits $4.7B valuation
Mediterranean restaurant chain Cava Group notched a valuation of $4.7 billion in a stellar market debut on Thursday, signaling the IPO market was gaining…
Mediterranean restaurant chain Cava Group notched a valuation of $4.7 billion in a stellar market debut on Thursday, signaling the IPO market was gaining momentum after a lull in 2022.
Shares opened at $42 apiece on the NYSE, nearly double the IPO price of $22, last up 89%. Cava sold about 14.4 million shares in the offering, raising $318 million.
Investors are warming up to IPOs this year after a volatility-fueled 2022 curbed appetite for new listings and fueled a risk-off sentiment.
“The fact that CAVA is unprofitable and generating this level of interest is certainly an important development,” Matthew Kennedy, senior IPO market strategist at Renaissance Capital told Reuters, adding that IPO activity will gradually normalize in the second half of the year.
Last month, Johnson & Johnson’s consumer health business, Kenvue, completed the largest IPO since Rivian Automotive listed in 2021.
The fast-casual restaurant industry has posted strong sales in recent months despite concerns of a looming recession in the United States.
“We think the markets are always welcoming long-term sustainable growth stories, especially category defining brands, as we try and define the Mediterranean category,” Cava co-founder and CEO Brett Schulman said.
So far this year, listed peers such as Chipotle Mexican Grill and Shake Shack have risen more than 48% each, outpacing the rise in shares of fast-food brands McDonald’s and Restaurant Brands International.
Cava was founded by three friends with Greek roots — Ted Xenohristos, Ike Grigoropoulos and Dimitri Moshovitis — and opened its first restaurant Cava Mezze in Rockville in 2006.
It started selling its signature dips and spreads in local grocery stores within two years of establishing its first outlet.
JPMorgan, Jefferies and Citigroup were the joint lead book-running managers for Cava’s offering.
The post Cava soars in stock market debut — hits $4.7B valuation appeared first on REPORT DOOR.
dimitri-
Law & Regulation1 week ago
FDA to weigh safety, impact of MDMA therapy for PTSD at June meeting
-
Psychedelics1 week ago
Optimi Health Receives Export Permit from Health Canada to Ship MDMA To Tel Aviv University’s Institute for Psychedelic Research
-
Ketamine1 week ago
Clinical-Stage BioTech Drug Stocks Portfolio UP 7% In w/e May 3rd
-
Psychedelics1 week ago
Optimi Health Provides Corporate Update
-
Law & Regulation1 week ago
Horizons talk shifts from investors to insurance
-
Law & Regulation1 week ago
DEA psychedelics ban hearing halted by lawsuit
-
Law & Regulation6 days ago
Relmada loses another $21.8M, makes progress with clinical trials
-
Psychedelics5 days ago
BetterLife Obtains Excellent Animal Cardiopulmonary Safety Data for Oral BETR-001